PROSHARES ULTRASHORT S&P500
SymbolSDS

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Pomerantz Law Firm Files Action on Behalf of Investors in ProShares' UltraShort S&P 500 Fund -- SDS

2009-11-03 15:30 ET - News Release

NEW YORK, Nov. 3, 2009 (GLOBE NEWSWIRE) -- Pomerantz Haudek Grossman & Gross LLP has filed a class action (09-cv-9077) on behalf of investors of ProShares' UltraShort S&P Fund (NYSE:SDS) who purchased or otherwise acquired shares in the SDS Fund, an exchange-traded fund ("ETF") offered by ProShares Trust ("ProShares"), pursuant or traceable to ProShares' false and misleading Registration Statement, Prospectuses, and Statements of Additional Information issued in connection with the SDS Fund's shares.

The SDS Fund is an inverse leveraged ETF that seeks investment returns that are two times the inverse performance of the S&P 500 Index. The case centers on the allegation that the registration statement filed by ProShares failed to adequately disclose that SDS shares should not be held more than a single trading day and were not an appropriate hedge against a decline in U.S. based stocks.

Specifically, the complaint alleges, among other things, that The Registration Statement misled investors that the SDS Fund would deliver double the inverse return of the S&P 500 Indes ("SPX"). ProShares' Registration Statement provides hypothetical examples of fees that investors may encounter over I-year, 3-year, 5-year, and 10-year periods, thereby misleading investors that the SDS Fund may be used for intermediate or long-term investing. The Registration Statement did not explain that, notwithstanding the name of the SDS Fund, the investment objective of the SDS Fund, and the purpose of ProShares' UltraShort ETFs, the SDS Fund would - to a mathematical certainty -- cause enormous losses if used for intennediate or long-term investing. The enormous losses are accelerated when the market becomes more volatile.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.